Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Bayer price target lowered to EUR 68 from EUR 82 at Morgan Stanley » 11:42
10/21/20
10/21
11:42
10/21/20
11:42
BAYRY

Bayer

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
10/02/20 Deutsche Bank
Bayer price target lowered to EUR 64 from EUR 82 at Deutsche Bank
BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

Hot Stocks
Abbott sees COVID-19 testing as a 'growth driver'  09:55
10/21/20
10/21
09:55
10/21/20
09:55
ABT

Abbott

$107.74 /

-0.66 (-0.61%)

 
ShowHide Related Items >><<
ABT Abbott
$107.74 /

-0.66 (-0.61%)

ABT Abbott
$107.74 /

-0.66 (-0.61%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$107.74 /

-0.66 (-0.61%)

ABT Abbott
$107.74 /

-0.66 (-0.61%)

ABT Abbott
$107.74 /

-0.66 (-0.61%)

ABT Abbott
$107.74 /

-0.66 (-0.61%)

Hot Stocks
Abbott says seeing 'signs of recovery' in areas hit hardest from COVID-19 » 09:37
10/21/20
10/21
09:37
10/21/20
09:37
ABT

Abbott

$108.40 /

+0.33 (+0.31%)

Says expects momentum to…

Says expects momentum to carry into 2021. Expects COVID-19 testing to be "big boost" for the company. Expects demand for COVID-19 tests to remain high through 2021. Says generating "nice cash," and does not see any change to capital allocation strategy. Says FreeStyle Libre is a "platform" for mass-market penetration and there will be continued innovation in products. Comments taken from Q3 earnings conference call.

ShowHide Related Items >><<
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

Earnings
Abbott sees double-digit sales, EPS growth in Q4 » 09:15
10/21/20
10/21
09:15
10/21/20
09:15
ABT

Abbott

$108.40 /

+0.33 (+0.31%)

Q4 EPS/revenue consensus…

Q4 EPS/revenue consensus $1.21/$9.6B, respectively

ShowHide Related Items >><<
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

Hot Stocks
PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA » 08:35
10/21/20
10/21
08:35
10/21/20
08:35
PTCT

PTC Therapeutics

$51.40 /

-0.72 (-1.38%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

PTC Therapeutics (PTCT)…

PTC Therapeutics (PTCT) tannounced that Evrysdi was approved in Brazil by the National Health Surveillance Agency for the treatment of spinal muscular atrophy. The approval was obtained within seven months of Roche's (RHHBY) initial submission and marks the second country to approve Evrysdi. Additionally, PTC announced the filing of a New Drug Application for Evrysdi for the treatment of SMA with the Japanese Ministry of Health, Labor and Welfare. The filing in Japan by Chugai Pharmaceutical Co. Ltd., a member of the Roche group, triggers a $7.5M milestone payment to PTC from Roche.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

10/07/20 JPMorgan
PTC Therapeutics upgraded to Overweight with $71 target at JPMorgan
10/07/20 JPMorgan
PTC Therapeutics upgraded to Overweight from Neutral at JPMorgan
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
08/24/20 Raymond James
PTC Therapeutics initiated with an Outperform at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

Periodicals
Eli Lilly hires advisor to review plant producing C-19 treatment, CNBC reports » 08:26
10/21/20
10/21
08:26
10/21/20
08:26
LLY

Eli Lilly

$143.57 /

+0.93 (+0.65%)

Eli Lilly has hired an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

10/16/20 JPMorgan
Eli Lilly price target raised to $200 from $190 at JPMorgan
10/14/20 JPMorgan
Eli Lilly risk/reward favorable into tirzepatide readout, says JPMorgan
10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
10/08/20 Benchmark
Regeneron antibody data 'more convincing' than Eli Lilly's, says Benchmark
LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

Hot Stocks
Abbott CEO says 'new product pipeline continues to be highly productive' » 07:37
10/21/20
10/21
07:37
10/21/20
07:37
ABT

Abbott

$108.40 /

+0.33 (+0.31%)

"Our strong results…

"Our strong results and increased guidance are a direct reflection of our ability to innovate and deliver despite challenging conditions," said Robert Ford, president and CEO, Abbott. "Our new product pipeline continues to be highly productive, and we're well-positioned to finish the year with a lot of momentum."

ShowHide Related Items >><<
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

Hot Stocks
Abbott reports Q3 FreeStyle Libre growth of 37.9% on reported basis » 07:35
10/21/20
10/21
07:35
10/21/20
07:35
ABT

Abbott

$108.40 /

+0.33 (+0.31%)

In Diabetes Care, strong…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

Hot Stocks
Abbott reports Q3 Worldwide Medical Devices sales up 3.4% on reported basis » 07:32
10/21/20
10/21
07:32
10/21/20
07:32
ABT

Abbott

$108.40 /

+0.33 (+0.31%)

Worldwide Medical Devices…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

Earnings
Abbott raises FY20 adjusted EPS view to 'at least' $3.55 from 'at least' $3.25  07:31
10/21/20
10/21
07:31
10/21/20
07:31
ABT

Abbott

$108.40 /

+0.33 (+0.31%)

FY20 consensus $3.32.

ShowHide Related Items >><<
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
10/09/20 JPMorgan
Abbott price target raised to $125 from $110 at JPMorgan
10/07/20 Wells Fargo
Abbott price target raised to $122 from $120 at Wells Fargo
10/06/20 Canaccord
Quanterix price target raised to $40 from $38 at Canaccord
ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

ABT Abbott
$108.40 /

+0.33 (+0.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.